Shijiazhuang purchasing agent (Nexavar, India) 15011127273 (Gleevec price)

Chinese Pinyin: Changsha sells Indian Nexavar, Indian Nexavar purchasing agent 3 Ms. Wang
Properties: This product is a red round tablet
Indications: Treatment of inoperable advanced renal cell carcinoma.
Treatment of primary hepatocellular carcinoma that is inoperable or has distant metastasis.
There is currently a lack of randomized controlled clinical study data comparing sorafenib with interventional treatments such as hepatic artery embolization and chemoembolization () in patients with advanced stem cell cancer.
Therefore, the advantages and disadvantages of this product relative to interventional treatments cannot yet be clarified. , and it is unclear whether the use of sorafenib is beneficial to patients who have previously undergone interventional therapy.
It is recommended that doctors consider the specific situation and choose appropriate treatment methods.
Specifications: Tablets/Box
Usage and Dosage: The recommended dose of sorafenib is one tablet per time, twice a day, on an empty stomach or with a low-fat or medium-fat diet.
Instructions for taking: Orally, swallow with a glass of warm water.
Treatment duration: Treatment should be continued until the patient cannot benefit clinically or develops intolerable toxicity.
Dosage adjustment and special instructions for use: Management of suspected adverse reactions includes suspending or reducing the dosage of sorafenib, if necessary, reducing the dosage of sorafenib to once daily, each time. ( piece).
Listed below are recommendations for dose adjustments based on skin toxicity.
Grading of skin adverse reactions and corresponding dosage adjustments
Grading of adverse reactions: paralysis, hypoesthesia, abnormal sensation, numbness, painless swelling, erythema or discomfort on hands and feet but does not affect daily activities.
Frequency of adverse reactions: occurring at any time.
Recommended dose adjustment: Continue to use this product and provide local treatment to eliminate symptoms. .